Complete and print.

Reset Form

MAYO CLINIC LABORATORIES

# Oncology Test Request

## Client Information (required)

| | | |
|---|---|---|
| Client Name | | |
| Client Account No. | | |
| Client Phone | Client Order No. | |
| Street Address | | |
| City | State | ZIP Code |

## Submitting Healthcare Professional Information (required)

| |
|---|
| Submitting/Referring Healthcare Professional Name (Last, First) |

**Fill in only if Call Back is required.**

| | |
|---|---|
| Phone (with area code) | Fax* (with area code) |
| National Provider Identification (NPI) | |

**Fax number given must be from a fax machine that complies with applicable HIPAA regulation.*

## Pathologist Information (required)

| | |
|---|---|
| Submitting/Referring Pathologist Name (Last, First) | |
| Phone (with area code) | Fax* (with area code) |
| National Provider Identification (NPI) | |

**Fax number given must be from a fax machine that complies with applicable HIPAA regulation.*

**New York State Patients: Informed Consent for Genetic Testing**

"I hereby confirm that informed consent has been signed by an individual legally authorized to do so and is on file with this office or the individual's provider's office."

Signature ▶

**Note:** It is the client's responsibility to maintain documentation of the order.

**MCL Internal Use Only**

**Ship specimens to:**
Mayo Clinic Laboratories
3050 Superior Drive NW
Rochester, MN 55905

**Customer Service: 800-533-1710**

Visit www.MayoClinicLabs.com for the most up-to-date test and shipping information.

## Patient Information (required)

| | |
|---|---|
| Patient ID (Medical Record No.) | |
| Patient Name (Last, First Middle) | |
| Sex ☐ Male ☐ Female | Birth Date (mm-dd-yyyy) |
| Collection Date (mm-dd-yyyy) | Time ☐ am ☐ pm |

## Specimens Provided

| | | |
|---|---|---|
| ☐ Blood<br>☐ Bone marrow<br>☐ Fixed cells<br>☐ Cultured cells<br>☐ DNA<br>☐ Lymph node<br>☐ Spleen | ☐ Paraffin block<br>No. sent:<br>Indicate source:<br><br>☐ Slides<br>No. sent: | ☐ Tissue<br>No. sent:<br>☐ Frozen<br>☐ Fixed formalin<br>☐ Wet tissue<br>☐ Other fixative<br>Type:<br><br>☐ Other<br>Anatomic site: |

CBC Results

| | | |
|---|---|---|
| HB: | RBC: | WBC: |
| HCT: | MCV: | PLT: |

**If ordering HER2 testing:**

Was specimen fixed in 10% neutral buffered formalin within 1 hour of surgical collection time? ☐ Yes ☐ No

Has specimen been fixed in 10% neutral buffered formalin for 6 to 72 hours? ☐ Yes ☐ No

## Pathologist/Clinical Diagnosis (required)

*Include a brief history, pertinent laboratory results, suspected diagnosis, and reason for referral.*

ICD-10 Diagnosis Code

**Billing Information**

- An itemized invoice will be sent each month.
- Payment terms are net 30 days.

Call the Business Office with billing-related questions:
800-447-6424 (US and Canada)
507-266-5490 (outside the US)



©2026 Mayo Foundation for Medical Education and Research

## Patient Information (required)

| | |
|---|---|
| Patient ID (Medical Record No.) | Client Account No. |
| Patient Name (Last, First Middle) | Client Order No. |
| Birth Date (mm-dd-yyyy) | |

# FEATURED ONCOLOGY TESTING

### PD-L1 Immunohistochemical stains

- ☐ 22C3 — Programmed Death-Ligand 1 (PD-L1) (22C3), Semi-Quantitative Immunohistochemistry, Manual
- ☐ 288PD — Programmed Death-Ligand 1 (PD-L1) (28-8), Semi-Quantitative Immunohistochemistry, Manual
- ☐ SP142 — Programmed Death-Ligand 1 (PD-L1) (SP142), Semi-Quantitative Immunohistochemistry, Manual
- ☐ SP263 — Programmed Death-Ligand 1 (PD-L1) (SP263), Semi-Quantitative Immunohistochemistry, Manual

### Microsatellite Instability (MSI)/Mismatch Repair

- ☐ TMSI — Microsatellite Instability, Tumor
- ☐ IHC — Mismatch Repair (MMR) Protein Immunohistochemistry Only, Tumor

### Pan-Cancer Biomarkers

- ☐ BRAFD — *BRAF* V600E/V600K Somatic Mutation Analysis, Tumor
- ☐ MCRSP — MayoComplete Targeted RNA Sequencing Panel, Next-Generation Sequencing, Tumor
- ☐ NTRKM — *NTRK* Genes Mutation Analysis, Next-Generation Sequencing, Tumor

### Next-Generation Sequencing (NGS) Panels

- ☐ MCBPP — MayoComplete Bladder and Prostate Cancer Panel, Next-Generation Sequencing, Tumor
- ☐ MCCRC — MayoComplete Colorectal Cancer Panel, Next-Generation Sequencing, Tumor
- ☐ MCSRC — MayoComplete Comprehensive Sarcoma Panel, Next-Generation Sequencing, Tumor
- ☐ MCECP — MayoComplete Endometrial Carcinoma Panel, Next-Generation Sequencing, Tumor
- ☐ MCGST — MayoComplete Gastrointestinal Stromal Tumor (GIST) Panel, Next-Generation Sequencing, Tumor
- ☐ MCGYN — MayoComplete Gynecological Cancer Panel, Next-Generation Sequencing, Tumor
- ☐ MCKCP — MayoComplete Kidney Cancer Panel, Next-Generation Sequencing, Tumor
- ☐ MCLNM — MayoComplete Lung Cancer Mutations, Next-Generation Sequencing, Tumor
- ☐ MCLNR — MayoComplete Lung Rearrangements, Rapid Test, Tumor
- ☐ MCLNG — MayoComplete Lung Cancer-Targeted Gene Panel with Rearrangement, Tumor
- ☐ MCMLN — MayoComplete Melanoma Panel, Next-Generation Sequencing, Tumor
- ☐ MCSTP — MayoComplete Solid Tumor Panel, Next-Generation Sequencing, Tumor
- ☐ MCOCP — MayoComplete Ovarian, Fallopian Tube, and Peritoneal Cancer Panel, Next-Generation Sequencing, Tumor
- ☐ MCFRC — MayoComplete Renal Cell Carcinoma with Fibromyomatous Stroma Panel, Next-Generation Sequencing, Tumor
- ☐ MCRSP — MayoComplete Targeted RNA Sequencing Panel, Next-Generation Sequencing, Tumor
- ☐ NONCP — Neuro-Oncology Expanded Gene Panel with Rearrangement, Tumor

### Chromosomal Microarray

- ☐ CMAPT — Chromosomal Microarray, Tumor, Formalin-Fixed Paraffin-Embedded

### Cell-Free DNA (cfDNA) Testing

- ☐ BRAFB — Cell-Free DNA *BRAF* V600, Blood
- ☐ T790M — Cell-Free DNA *EGFR* T790M Mutation Analysis, Blood
- ☐ KRASD — Cell-Free DNA *KRAS* 12, 13, 61, 146, Blood
- ☐ MCLBP — MayoComplete Liquid Biopsy Panel, Next-Generation Sequencing, Cell-Free DNA

### Genome Wide Methylation

- ☐ MTNON — Neuro-Oncology Genome-Wide Methylation Array Analysis, Tumor

## PATHOLOGY

- ☐ PATHC — Pathology Consultation
  Appropriate stains and ancillary testing may be performed in order to render an accurate diagnosis

## PATHOLOGY: TARGETED TUMOR TESTING

### Bone and Soft Tissue

- ☐ FOXOF — Alveolar Rhabdomyosarcoma (ARMS), 13q14 *(FOXO1* or *FKHR)* Rearrangement, FISH, Tissue
- ☐ TFE3F — Alveolar Soft Part Sarcoma (ASPS)/ Renal Cell Carcinoma (RCC), Xp11.23 *(TFE3)*, FISH, Tissue
- ☐ MASF — Angiosarcoma, *MYC* (8q24) Amplification, FISH, Tissue
- ☐ CTNBT — B-Catenin Mutations Analysis, Next-Generation Sequencing, Tumor
- ☐ DICET — *DICER1* Mutation Analysis, Next-Generation Sequencing, Tumor
- ☐ ETV6F — *ETV6* (12p13.2) Rearrangement, FISH, Tissue
- ☐ ESTUF — Endometrial Stromal Tumors (EST), 7p15 *(JAZF1)*, 6p21.32 *(PHF1)*, 17p13.3 *(YWHAE)* Rearrangement, FISH, Tissue
- ☐ EWSF — Ewing Sarcoma, 22q12 *(EWSR1)* Rearrangement, FISH, Tissue
- ☐ IMTF — Inflammatory Myofibroblastic Tumors (IMT), 2p23 *(ALK)* Rearrangement, FISH, Tissue
- ☐ FUSF — Low-Grade Fibromyxoid Sarcoma (LGFMS), 16p11.2 *(FUS* or *TLS)* Rearrangement, FISH, Tissue
- ☐ MDM2F — *MDM2* (12q15) Amplification, *Well*-Differentiated Liposarcoma/ Atypical Lipomatous Tumor, FISH, Tissue
- ☐ MYODT — *MYOD1* Mutation Analysis, Next-Generation Sequencing, Tumor
- ☐ DDITF — Myxoid/Round Cell Liposarcoma, 12q13 *(DDIT3* or *CHOP)* Rearrangement, FISH, Tissue
- ☐ NR4A3 — *NR4A3* (9q22.33) Rearrangement, FISH, Tissue
- ☐ PDGF — *PDGFB* (22q13), Dermatofibrosarcoma Protuberans/Giant Cell Fibroblastoma, FISH, Tissue
- ☐ SS18F — Synovial Sarcoma (SS), 18q11.2 *(SS18* or *SYT)* Rearrangement, FISH, Tissue
- ☐ TGOGF — TGFBR3 (1p22), OGA (10q24) Rearrangement, FISH, Tissue
- ☐ USPF — *USP6* (17p13), Aneurysmal Bone Cyst and Nodular Fasciitis, FISH, Tissue

### Breast

- ☐ MASF — Angiosarcoma, *MYC* (8q24) Amplification, FISH, Tissue
- ☐ BRCAT — *BRCA1/2* Mutation Analysis, Next-Generation Sequencing, Tumor
- ☐ PIK3B — Cell-Free DNA PIK3CA Test, Blood
- ☐ ESR1T — *ESR1* Mutations Analysis, Next-Generation Sequencing, Tumor
- ☐ FGF1F — *FGFR1* (8p11.2) Amplification, FISH, Tissue
- ☐ H2BR — *HER2* Amplification Associated with Breast Cancer, FISH, Tissue
- ☐ ETV6F — *ETV6* (12p13.2) Rearrangement, FISH, Tissue
- ☐ PIK3T — *PIK3CA* Mutation Analysis, Tumor

**Immunohistochemical assays interpreted with digital image analysis**

- ☐ ERPR — Estrogen/Progesterone Receptor, Semi-Quantitative Immunohistochemistry, Manual
- ☐ KI67B — Ki-67(MIB-1), Breast, Quantitative Immunohistochemistry, Automated
- ☐ HERBA — HER2, Breast, Quantitative Immunohistochemistry, Automated with HER2 FISH Reflex



T729
MC0767-03Arev0526

## Patient Information (required)

| Patient ID (Medical Record No.) | Client Account No. |
|---|---|
| Patient Name (Last, First Middle) | Client Order No. |
| Birth Date (mm-dd-yyyy) | |

### Gastrointestinal

- ☐ BRAFD — *BRAF* V600E/V600K Somatic Mutation Analysis, Tumor
- ☐ EGFRS — *EGFR* Gene, Targeted Mutation Analysis, 51 Mutation Panel, Tumor
- ☐ PRKAF — Fibrolamellar Carcinoma, 19p13.1 *(PRKACA)* Rearrangement, FISH, Tissue
- ☐ FGFR2 — *FGFR2* (10q26.1) Rearrangement, FISH, Tissue
- ☐ H2GE — *HER2* Amplification Associated with Gastroesophageal Cancer, FISH, Tissue
- ☐ H2MT — *HER2* Amplification, Miscellaneous Tumor, FISH, Tissue
- ☐ KINET — Ki-67(MIB-1), Gastrointestinal/Pancreatic Neuroendocrine Tumors, Quantitative Immunohistochemistry, Automated
- ☐ METF — *MET* (7q31), FISH, Tissue
- ☐ ML1HM — *MLH1* Hypermethylation Analysis, Tumor
- ☐ MLHPB — *MLH1* Hypermethylation Analysis, Blood
- ☐ BRMLH — *MLH1* Hypermethylation and *BRAF* Mutation Analysis, Tumor
- ☐ IHC — Mismatch Repair (MMR) Protein Immunohistochemistry Only, Tumor
- ☐ TMSI — Microsatellite Instability, Tumor

### Genitourinary

- ☐ TFE3F — Alveolar Soft Part Sarcoma (ASPS)/ Renal Cell Carcinoma (RCC), Xp11.23 *(TFE3)*, FISH, Tissue
- ☐ GCTF — Germ Cell Tumor (GCT), Isochromosome 12p, FISH, Tissue
- ☐ H2MT — *HER2* Amplification, Miscellaneous Tumor, FISH, Tissue
- ☐ MCKCP — MayoComplete Kidney Cancer Panel, Next-Generation Sequencing, Tumor
- ☐ FUROC — UroVysion for Detection of Bladder Cancer, Urine
- ☐ MCBPP — MayoComplete Bladder and Prostate Cancer Panel, Next-Generation Sequencing, Tumor
- ☐ MCFRC — MayoComplete Renal Cell Carcinoma with Fibromyomatous Stroma Panel, Next-Generation Sequencing, Tumor
- ☐ NUT1F — *NUTM1* (15q14) Rearrangement, FISH, Tissue
- ☐ TFEBF — Renal Cell Carcinoma, 6p21.1 *(TFEB)* Rearrangement, FISH, Tissue
- ☐ SDHMP — *SDH* Genes Mutation Analysis, Next-Generation Sequencing, Tumor
- ☐ TFH — *FH* Mutation Analysis, Next-Generation Sequencing, Tumor

### Gynecology

**Endometrial/Uterine Carcinoma**

- ☐ ESTUF — Endometrial Stromal Tumors (EST), 7p15 *(JAZF1)*, 6p21.32 *(PHF1)*, 17p13.3 *(YWHAE)* Rearrangement, FISH, Tissue
- ☐ MCGYN — MayoComplete Gynecological Cancer Panel, Next-Generation Sequencing, Tumor
- ☐ MCECP — MayoComplete Endometrial Carcinoma Panel, Next-Generation Sequencing, Tumor
- ☐ ML1HM — *MLH1* Hypermethylation Analysis, Tumor
- ☐ POLET — *POLE* Mutation Analysis, Next-Generation Sequencing, Tumor

**Ovarian Carcinoma**

- ☐ XL2T — *FOXL2* Mutations Analysis, Next-Generation Sequencing, Tumor
- ☐ MCOCP — MayoComplete Ovarian, Fallopian Tube, and Peritoneal Cancer Panel, Next-Generation Sequencing, Tumor

**Lower Anal-Genital Tract Carcinoma**

- ☐ HPVHL — Human Papillomavirus (HPV) High/Low Risk, In Situ Hybridization
- ☐ HPVE6 — Human Papillomavirus (HPV) High-Risk E6/E7, RNA In Situ Hybridization
- ☐ HPVLR — Human Papillomavirus (HPV), Low-Risk, In Situ Hybridization

### Head and Neck

- ☐ FGF1F — *FGFR1* (8p11.2) Amplification, FISH, Tissue
- ☐ HPVHL — Human Papillomavirus (HPV) High/Low Risk, In Situ Hybridization
- ☐ HPVE6 — Human Papillomavirus (HPV) High-Risk E6/E7, RNA In Situ Hybridization
- ☐ HPVLR — Human Papillomavirus (HPV), Low-Risk, In Situ Hybridization
- ☐ MAMLF — *MAML2* (11q21) Rearrangement, Mucoepidermoid Carcinoma (MEC), FISH, Tissue
- ☐ SGTF — *MYB* (6q23) Rearrangement, FISH, Tissue

### Melanoma

- ☐ BRAFB — Cell-Free DNA *BRAF* V600, Blood
- ☐ BRAFD — *BRAF* V600E/V600K Somatic Mutation Analysis, Tumor
- ☐ BRFKT — *BRAF* and *KIT* Mutation Analysis, Next-Generation Sequencing, Tumor
- ☐ NONCM — Neuro-Oncology Gene Panel, Mutations Only, Tumor
- ☐ MCRSP — MayoComplete Targeted RNA Sequencing Panel, Next-Generation Sequencing, Tumor

### Neuro-Oncology

- ☐ GLIOF — 1p/19q Deletion in Gliomas, FISH, Tissue
- ☐ ALKT — *ALK* Mutation Analysis, Next-Generation Sequencing, Tumor
- ☐ BRAFD — *BRAF* V600E/V600K Somatic Mutation Analysis, Tumor
- ☐ CMAPT — Chromosomal Microarray, Tumor, Formalin-Fixed Paraffin-Embedded
- ☐ GCTF — Germ Cell Tumor (GCT), Isochromosome 12p, FISH, Tissue
- ☐ HISGT — Histone Genes Mutation Analysis, Next-Generation Sequencing, Tumor
- ☐ IDHT — *IDH1* and *IDH2* Mutations Analysis, Next-Generation Sequencing, Tumor
- ☐ IDTRT — *IDH1*, *IDH2*, and TERT Mutation Analysis, Next-Generation Sequencing, Tumor
- ☐ MGMTD — *MGMT* Promoter Methylation Analysis, Tumor
- ☐ MTNON — Neuro-Oncology Genome-Wide Methylation Array Analysis, Tumor
- ☐ NONCP — Neuro-Oncology Expanded Panel with Rearrangement, Tumor
- ☐ TERTD — *TERT* Promoter Mutation Analysis, Droplet Digital PCR, Tumor
- ☐ TP53 — *TP53* Mutation Analysis, Next-Generation Sequencing, Tumor

### Pulmonary

- ☐ ALKT — *ALK* Mutation Analysis, Next-Generation Sequencing, Tumor
- ☐ BRAFD — *BRAF* V600E/V600K Somatic Mutation Analysis, Tumor
- ☐ EGFRS — *EGFR* Gene, Targeted Mutation Analysis, 51 Mutation Panel, Tumor
- ☐ EGFRW — EGFR Targeted Mutation Analysis with ALK Reflex, Tumor
- ☐ FGF1F — *FGFR1* (8p11.2) Amplification, FISH, Tissue
- ☐ KRASP — *KRAS* Somatic Mutation Analysis, Tumor
- ☐ LCAF — Lung Cancer, *ALK* (2p23) Rearrangement, FISH, Tissue
- ☐ RETF — Lung Cancer, *RET* (10q11) Rearrangement, FISH, Tissue
- ☐ ROS1F — Lung Cancer, *ROS1* (6q22) Rearrangement, FISH, Tissue
- ☐ MESOF — Mesothelioma, *CDKN2A* Fish, Tissue
- ☐ METF — *MET* (7q31), FISH, Tissue

### HEREDITARY ONCOLOGY TESTING

- ☐ BAP1Z — *BAP1*-Tumor Predisposition Syndrome, *BAP1* Full Gene Analysis
- ☐ BHDZ — Birt-Hogg-Dube Syndrome, *FLCN*, Full Gene Analysis
- ☐ HBOCZ — *BRCA1/BRCA2* Genes, Full Gene Analysis
- ☐ BRGYP — Hereditary Breast/Gynecologic Cancer Panel
- ☐ COMCP — Hereditary Common Cancer Panel
- ☐ CDHZ — Hereditary Diffuse Gastric Cancer Syndrome, *CDH1*, Full Gene Analysis
- ☐ ENDCP — Hereditary Endocrine Cancer Panel
- ☐ XCP — Hereditary Expanded Cancer Panel
- ☐ CRCGP — Hereditary Gastrointestinal Cancer Panel

## Patient Information (required)

| Patient ID (Medical Record No.) | Client Account No. |
|---|---|
| Patient Name (Last, First Middle) | Client Order No. |
| Birth Date (mm-dd-yyyy) | |

- ☐ LRCCZ — Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome, *FH*, Full Gene Analysis
- ☐ PANCP — Hereditary Pancreatic Cancer Panel
- ☐ HPGLP — Hereditary Paraganglioma/ Pheochromocytoma Panel
- ☐ PRS8P — Hereditary Prostate Cancer Panel
- ☐ RENCP — Hereditary Renal Cancer Panel
- ☐ THYRP — Hereditary Thyroid Cancer Panel
- ☐ WILMP — Hereditary Wilms Tumor Panel
- ☐ LYNCP — Lynch Syndrome Panel
- ☐ RETZZ — Multiple Endocrine Neoplasia Type 2 Syndrome, *RET*, Full Gene Analysis
- ☐ NF1Z — Neurofibromatosis Type 1, *NF1*, Full Gene Analysis
- ☐ PTNZ — PTEN Hamartoma Tumor Syndrome, *PTEN* Full Gene Analysis
- ☐ STK1Z — Peutz-Jeghers Syndrome, *STK11*, Full Gene Analysis
- ☐ BRTP — Rapid Hereditary Breast Cancer Treatment Decision Panel
- ☐ UGTFZ — UDP-Glucuronosyltransferase 1A1 (UGT1A1), Full Gene Sequencing
- ☐ U1A1Q — UDP-Glucuronosyltransferase 1A1 TA Repeat Genotype, *UGT1A1*
- ☐ VHLZZ — Von Hippel Lindau Syndrome, *VHL*, Full Gene Analysis

## PRIMARY BODY FLUID TESTS TESTS FOR DISEASE MONITORING OR AIDING IN THE DIAGNOSIS

### Bone and Soft Tissue

- ☐ IFG23 — Intact Fibroblast Growth Factor 23, Serum

### Breast

- ☐ C2729 — Breast Carcinoma-Associated Antigen, Serum
- ☐ CA153 — Cancer Antigen 15-3 (CA 15-3), Serum

### Endocrine

**Thyroid Cancer**

- ☐ CATLN — Calcitonin, Fine-Needle Aspiration Biopsy Needle Wash, Lymph Node
- ☐ CATN — Calcitonin, Serum
- ☐ CEA — Carcinoembryonic Antigen (CEA), Serum
- ☐ TGMS — Thyroglobulin Mass Spectrometry, Serum
- ☐ TFNAB — Thyroglobulin, Tumor Marker, Fine-Needle Aspiration Biopsy Needle Wash
- ☐ HTGR — Thyroglobulin, Tumor Marker Reflex, Serum
- ☐ HTG2 — Thyroglobulin, Tumor Marker, Serum

**Neuroendocrine Tumors**

- ☐ CGAK — Chromogranin A, Serum
- ☐ GAST — Gastrin, Serum
- ☐ GLP — Glucagon, Plasma
- ☐ NSE — Neuron-Specific Enolase, Serum
- ☐ HPP — Pancreatic Polypeptide, Plasma
- ☐ VIP — Vasoactive Intestinal Polypeptide, Plasma

**Pituitary Tumors**

- ☐ ACTH — Adrenocorticotropic Hormone, Plasma
- ☐ APGH — Alpha-Subunit Pituitary Tumor Marker, Serum
- ☐ FSH — Follicle-Stimulating Hormone (FSH), Serum
- ☐ HGH — Growth Hormone, Serum
- ☐ LH — Luteinizing Hormone (LH), Serum
- ☐ MCRPL — Macroprolactin, Serum
- ☐ NSE — Neuron-Specific Enolase, Serum
- ☐ PLPMA — Prolactin, Pituitary Macroadenoma, Serum
- ☐ PRL — Prolactin, Serum

**Biogenic Amines**

- ☐ CATU — Catecholamine Fractionation, Free, 24 Hour, Urine
- ☐ CATP — Catecholamine Fractionation, Free, Plasma
- ☐ HVA — Homovanillic Acid, 24 Hour, Urine
- ☐ HVAR — Homovanillic Acid, Random, Urine
- ☐ HIAA — 5-Hydroxyindoleacetic Acid, 24 Hour, Urine
- ☐ METAF — Metanephrines, Fractionated, 24 Hour, Urine
- ☐ PMET — Metanephrines, Fractionated, Free, Plasma
- ☐ SERU — Serotonin, 24 Hour, Urine
- ☐ SERWB — Serotonin, Blood
- ☐ VH — Vanillylmandelic Acid and Homovanillic Acid, Random, Urine
- ☐ VMA — Vanillylmandelic Acid, 24 Hour, Urine
- ☐ VMAR — Vanillylmandelic Acid, Random, Urine

### Gastrointestinal

- ☐ L3AFP — Alpha-Fetoprotein (AFP) L3% and Total, Hepatocellular Carcinoma Tumor Marker, Serum
- ☐ AFPPT — Alpha-Fetoprotein (AFP), Peritoneal Fluid
- ☐ AFP — Alpha-Fetoprotein (AFP) Tumor Marker, Serum
- ☐ AMLPC — Amylase, Pancreatic Cyst Fluid
- ☐ 199PC — Carbohydrate Antigen 19-9 (CA 19-9), Pancreatic Cyst Fluid
- ☐ 199PT — Carbohydrate Antigen 19-9 (CA 19-9), Peritoneal Fluid
- ☐ CA19 — Carbohydrate Antigen 19-9 (CA 19-9), Serum
- ☐ CEAPC — Carcinoembryonic Antigen (CEA), Pancreatic Cyst Fluid
- ☐ CEAPT — Carcinoembryonic Antigen (CEA), Peritoneal Fluid
- ☐ CEA — Carcinoembryonic Antigen (CEA), Serum
- ☐ CGAK — Chromogranin A, Serum
- ☐ DCP — Des-Gamma-Carboxy Prothrombin, Serum
- ☐ FOBT — Fecal Occult Blood, Colorectal Cancer Screen, Qualitative, Immunochemical, Feces
- ☐ GAST — Gastrin, Serum
- ☐ GLP — Glucagon, Plasma
- ☐ GLBF — Glucose, Body Fluid
- ☐ HCCGS — Hepatocellular Carcinoma Risk Panel with GALAD Score, Serum
- ☐ HIAA — 5-Hydroxyindoleacetic Acid, 24 Hour, Urine
- ☐ NSE — Neuron-Specific Enolase, Serum
- ☐ HPP — Pancreatic Polypeptide, Plasma
- ☐ SERU — Serotonin, 24 Hour, Urine
- ☐ SERWB — Serotonin, Blood
- ☐ VIP — Vasoactive Intestinal Polypeptide, Plasma

### Genitourinary

- ☐ AFPSF — Alpha-Fetoprotein (AFP), Spinal Fluid
- ☐ AFP — Alpha-Fetoprotein (AFP) Tumor Marker, Serum
- ☐ BHCG — Beta-Human Chorionic Gonadotropin, Quantitative, Serum
- ☐ BHSF — Beta-Human Chorionic Gonadotropin, Quantitative, Spinal Fluid
- ☐ CEASF — Carcinoembryonic Antigen (CEA), Spinal Fluid
- ☐ PSA — Prostate-Specific Antigen (PSA) Diagnostic, Serum
- ☐ SPSA — Prostate-Specific Antigen (PSA) Screen, Serum
- ☐ PHI11 — Prostate Health Index Reflex, Serum
- ☐ PSAFT — Prostate-Specific Antigen (PSA), Total and Free, Serum

### Gynecology

- ☐ BHCG — Beta-Human Chorionic Gonadotropin, Quantitative, Serum
- ☐ CA25 — Cancer Antigen 125 (CA 125), Serum
- ☐ HE4 — Human Epididymis Protein 4, Serum
- ☐ INHA — Inhibin A, Tumor Marker, Serum
- ☐ INHAB — Inhibin A and B, Tumor Marker, Serum
- ☐ INHB — Inhibin B, Serum
- ☐ ROMA — ROMA Score (Ovarian Malignancy Risk Algorithm), Serum

### Pulmonary

- ☐ PF199 — Carbohydrate Antigen 19-9 (CA 19-9), Pleural Fluid
- ☐ PFCEA — Carcinoembryonic Antigen (CEA), Pleural Fluid
- ☐ NSE — Neuron-Specific Enolase (NSE), Serum

## ADDITIONAL TESTS (INDICATE TEST ID AND NAME)



Print

T729
MC0767-03Arev0526